| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/13/2003 | US20030031694 Controlled release particles |
| 02/13/2003 | US20030031677 Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications |
| 02/13/2003 | US20030031676 Conjugate compounds for treating atheroma and other diseases |
| 02/13/2003 | US20030031674 Poly (ethylene glycol) copolymers |
| 02/13/2003 | US20030031671 Administering to pharmaceutically effective amount of an anti-cancer agent conjugated to a polyethylene glycol-conjugated antibody, wherein antibody is specific for colon cancer for reducing effects of colon cancer |
| 02/13/2003 | US20030031669 Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| 02/13/2003 | US20030031667 Human monoclonal antibodies to dendritic cells |
| 02/13/2003 | US20030031659 For the treatment or prevention of a gastrointestinal infection caused by a pathogenic bacteria; for reducing insect and parasite populations in animal manure |
| 02/13/2003 | US20030031631 Having surface tension, effective for therapy of respiratory systme disorders |
| 02/13/2003 | US20030031629 For use in diagnostic ultrasonic imaging |
| 02/13/2003 | CA2457100A1 Taste masking composition |
| 02/13/2003 | CA2455856A1 Targeted polymeric delivery systems |
| 02/13/2003 | CA2455843A1 Therapeutic delivery compositions and methods of use thereof |
| 02/13/2003 | CA2455777A1 Chitosan preparation |
| 02/13/2003 | CA2455638A1 Peptide-based multimeric targeted contrast agents |
| 02/13/2003 | CA2455598A1 Lipid constructs as therapeutic and imaging agents |
| 02/13/2003 | CA2455567A1 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| 02/13/2003 | CA2455347A1 Neutral glycosphingolipids and glycosyl-sphingosines and methods for isolating the same |
| 02/13/2003 | CA2455329A1 Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv |
| 02/13/2003 | CA2454918A1 Ophthalmic composition containing n-acetyl-cysteine for the treatment of dry-eye syndrome |
| 02/13/2003 | CA2454066A1 Pulmonary formulation |
| 02/13/2003 | CA2451868A1 Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety |
| 02/13/2003 | CA2451855A1 Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine |
| 02/13/2003 | CA2450770A1 Combination of selective cox-2 inhibitor and lung surfactant for respiratory syndrome |
| 02/13/2003 | CA2450123A1 Biodegradable polyhydric alcohol esters |
| 02/12/2003 | EP1283233A1 Polyoxyalkylene derivative and process of producing the same |
| 02/12/2003 | EP1283218A1 Compound comprising crosslinked polyrotaxane |
| 02/12/2003 | EP1283060A1 Preparations for diagnosing infection with helicobacter pylori |
| 02/12/2003 | EP1283059A2 Therapeutic conjugates of toxins and drugs |
| 02/12/2003 | EP1283053A1 Inhibitors of HER3 activity |
| 02/12/2003 | EP1283051A1 Stable insulin formulations |
| 02/12/2003 | EP1283044A2 Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| 02/12/2003 | EP1283042A1 Aqueous liquid preparation |
| 02/12/2003 | EP1283041A1 Pharmaceutical compositions containing HIV-protease inhibitors |
| 02/12/2003 | EP1283040A1 Sustained release oral preparations |
| 02/12/2003 | EP1283036A1 Dry powder for inhalation |
| 02/12/2003 | EP1283035A2 Therapeutic preparation for inhalation containing parathyroid hormone |
| 02/12/2003 | EP1283031A2 Skin treatment composition |
| 02/12/2003 | EP1282646A2 Human monoclonal antibodies to dendritic cells |
| 02/12/2003 | EP1282642A2 Therapeutic pore-forming peptides |
| 02/12/2003 | EP1282607A2 Prodrugs of hiv replication inhibiting pyrimidines |
| 02/12/2003 | EP1282448A1 Heterobifunctional cross-linking agent conjugate substituted by an immunomodulator and cell recognition unit |
| 02/12/2003 | EP1282447A1 Stable polymeric micelle-type drug composition and method for the preparation thereof |
| 02/12/2003 | EP1282446A1 Pharmaceutical and/or cosmetic composition containing an organosiloxane and a phospholipid |
| 02/12/2003 | EP1282429A1 Pharmaceutical gel composition |
| 02/12/2003 | EP1282422A1 Ciprofloxacin infusion solutions with improved storage life |
| 02/12/2003 | EP1282416A2 Dehydroascorbic acid formulations and uses thereof |
| 02/12/2003 | EP1282409A1 Insulin formulation for inhalation |
| 02/12/2003 | EP1282408A1 Hydrogel composition for transdermal drug delivery |
| 02/12/2003 | EP1282406A1 Pharmaceutical kit comprising midodrine as an active drug substance |
| 02/12/2003 | EP1282405A2 Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| 02/12/2003 | EP1282404A2 Method for preparing microparticles having a selected polymer molecular weight |
| 02/12/2003 | EP1282403A1 Non-invasive gene targeting to the brain |
| 02/12/2003 | EP1282402A1 Stabilized aqueous suspensions for parenteral use |
| 02/12/2003 | EP1282401A2 Stabilized steroidal suspension |
| 02/12/2003 | EP1282400A2 Pharmaceutical form of administration for peptides, methods for its production and use |
| 02/12/2003 | EP1282399A2 Rapidly disintegrating solid oral dosage form |
| 02/12/2003 | EP1282395A1 Use of ellagic acid as anti-pollution cosmetic agent |
| 02/12/2003 | EP1282393A1 External application for enhancing the skin permeability of the active components therein |
| 02/12/2003 | EP1135169B1 Use of a pharmaceutical composition comprising an anti-cancer agent and at least a peptide |
| 02/12/2003 | EP1109534B1 Quick release pharmaceutical compositions of drug substances |
| 02/12/2003 | EP0966299B1 Novel oral formulations of calcitonin |
| 02/12/2003 | EP0862456A4 Enzymatic method and compositions for treating intravitreal hemorrhagic blood |
| 02/12/2003 | EP0793497B1 Novel enediyne quinone imines and methods of preparation and use thereof |
| 02/12/2003 | EP0711154B1 Stabilized pharmaceutical composition containing bupropion |
| 02/12/2003 | CN1396927A Method for preparing polypeptide soluble in aqueous solvent in absence of detergent |
| 02/12/2003 | CN1396908A Palatable arginine compounds and uses thereof for cardiovascular health |
| 02/12/2003 | CN1396834A Stabilised pharmaceutical compositions and process for their preparation comprising antibiobic and expectorant |
| 02/12/2003 | CN1396830A Pharmaceutical parenteral composition containing biphosphonate |
| 02/12/2003 | CN1396828A Pharmaceutical composition comprising Pemetrexed together with monothioglycerol L-cystein or thioglycolic acid |
| 02/12/2003 | CN1396825A Composition, kit for benefitting cardiovasaclaire and method |
| 02/12/2003 | CN1396823A Electrospun pharmaceutical compositions |
| 02/12/2003 | CN1395968A Biological fluid dressing chitosan membrane and its preparing process |
| 02/12/2003 | CN1395964A Medical usage of simonder wood oil |
| 02/12/2003 | CN1101425C Stable aqueous dispersions and stable water-dispersible dry xanthophyll powder, there production and use |
| 02/12/2003 | CN1101389C Sugar compounds, gelling agents, gelling agent compositions, process for preparation of them and gel compositions |
| 02/12/2003 | CN1101228C Treatment of conditions and disease |
| 02/12/2003 | CN1101226C 疫苗 Vaccine |
| 02/12/2003 | CN1101191C Carbamazepine medicament with retarded active substance release |
| 02/12/2003 | CN1101187C Fluoxetine pharmaceutial formulations |
| 02/12/2003 | CN1101184C Process for preparing medical particles Qingkailing by wrapping chololic acid and animal extract with cyclodextrin |
| 02/12/2003 | CN1101181C Haemorrhoidal compositions and method of use |
| 02/12/2003 | CN1101146C Method for suppressing bitter taste |
| 02/11/2003 | WO2002092057A1 Tablets quickly disintegrating in the oral cavity and process for producing the same |
| 02/11/2003 | US6518269 Cancer treatment |
| 02/11/2003 | US6518239 Dry powder compositions having improved dispersivity |
| 02/11/2003 | US6518061 Interleukin-13 (IL-13); Delivery of a modified Pseudomonas exotoxin (effector molecule), attached to an interleukin, to tumor cells bearing interleukin receptors; antitumor agent |
| 02/11/2003 | US6518031 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 02/11/2003 | US6517871 Amorphous ammonium salt; blocking angiotensin II receptors; treating hypertension, congestive heart failure and renal failure |
| 02/11/2003 | US6517870 Improved taste by reducing bitterness and saltiness |
| 02/11/2003 | US6517869 Coupling such as DNA, RNA, oligonucleotides, proteins, peptides or drugs to free amino group |
| 02/11/2003 | US6517865 Water soluble cellulose ethers, hydrocolloides and sequestering agents. |
| 02/11/2003 | US6517864 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder |
| 02/11/2003 | US6517862 Containing trace elements |
| 02/11/2003 | US6517860 Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery |
| 02/11/2003 | US6517859 Injectable, drug delivery vehicles; controlled release of bioactive agents to sites within the central nervous system; dopamine, cholecystokinin, and epidermal and basic fibroblast growth factors for Parkinson's disease |
| 02/11/2003 | US6517854 Antimicrobial sanitizing lotion with skin protection properties |
| 02/11/2003 | US6517848 Method for sequestration of skin irritants with absorbent article composition |
| 02/11/2003 | US6517847 Topical gel delivery system |
| 02/11/2003 | US6517824 Liposome encapsulated copolymer conjugate; treating pulmonary hypertension and other diseases involving a defect in collagen metabolism; lysine and 4-hydroxyproline dipeptide covalently bound with polyether to form conjugate |